The Immunoscore in Localized Urothelial Carcinoma Treated with Neoadjuvant Chemotherapy: Clinical Significance for Pathologic Responses and Overall Survival

The Immunoscore in Localized Urothelial Carcinoma Treated with Neoadjuvant Chemotherapy: Clinical Significance for Pathologic Responses and Overall Survival

(1) Background—The five-year overall survival (OS) of muscle-invasive bladder cancer (MIBC) with neoadjuvant chemotherapy and cystectomy is around 50%. There is no validated biomarker to guide the treatment decision. We investigated whether the Immunoscore (IS) could predict the pathologic response...

Full description

Bibliographic Details
Main Authors: Elise F. Nassif, Bernhard Mlecnik, Constance Thibault, Marie Auvray, Daniela Bruni, Alexandre Colau, Eva Compérat, Gabriela Bindea, Aurélie Catteau, Aurélie Fugon, Isabelle Boquet, Marine Martel, Philippe Camparo, Pierre Colin, Roubini Zakopoulou, Aristotelis Bamias, Mostefa Bennamoun, Xavier Barthere, Bruno D’acremont, Marine Lefevre, Francois Audenet, Arnaud Mejean, Virginie Verkarre, Stéphane Oudard, Jérôme Galon
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Cancers
Subjects:
urothelial carcinoma
neoadjuvant chemotherapy
Immunoscore
prognostic score
predictive response to chemotherapy
immuno-oncology
Online Access:https://www.mdpi.com/2072-6694/13/3/494

Internet

https://www.mdpi.com/2072-6694/13/3/494

Similar Items